Hyperhidrosis treatment marketing: FDA and FTC rules

Excessive underarm sweating is a cash-pay draw for dermatology practices and med spas, and the ads tend to sound alike: “stop sweating for good,” “one treatment, permanent results,” “FDA approved for all sweating,” “sweat-free hands and feet.” The FDA record for hyperhidrosis treatments is narrower than that. Every device clearance and device grant we read, and each prescription drug label we found that names it as an indication, is limited to primary axillary hyperhidrosis, meaning underarm sweating without another medical cause, and several of them say so in plain words.

This guide walks through what FDA cleared, granted or approved for each type of treatment, what those records say about body areas, ages, duration and risks, and how FDA and FTC rules apply to a practice’s ads, reviews, photos and packages. We do not name any device, drug or brand. For the wider specialty, see our guide to dermatology practice marketing. Vitiligo treatments are covered in our guide to vitiligo treatment advertising.

This is general information, not legal or medical advice. Sources cited were checked on November 1, 2026: FDA product classification records for product codes OUB and QVX and the 510(k) and De Novo decisions under them, read through openFDA (device data last updated October 19, 2026); the 510(k) summaries and indications statements for K103014 (decision January 28, 2011), K131162 (October 25, 2013) and K150419 (June 19, 2015) and the De Novo decision summary for DEN210055 (granted April 7, 2023) on FDA’s accessdata site; prescribing information for FDA-approved drugs with a hyperhidrosis indication as listed in openFDA (drug label data last updated October 30, 2026); FDA’s page on unapproved uses of approved drugs (content current as of February 5, 2018); 21 CFR 878.4400, 878.4425, 807.97, 202.1, 16 CFR 255.2 and 233.1 in the eCFR version as of October 29, 2026; 21 USC 352 and 396 and 15 USC 45, 52 and 55 in the Cornell LII text of the U.S. Code; and the FTC Health Products Compliance Guidance (December 2022). We did not review the medical literature on hyperhidrosis, ad platform policies, or state rules on who may perform these treatments.

The short version

Underarms, not everywhere. The device clearances and grant we read, and the three prescription drug labels in openFDA indicated for it by name, are for primary axillary hyperhidrosis. One device clearance says outright that it is not indicated for other body areas or generalized hyperhidrosis.
Each route has its own record. Devices come through 510(k) clearance or De Novo, drugs through approval. Use the right word for the product you actually use (21 CFR 807.97).
Duration is a claim. The injectable label reports a median duration of response, and the De Novo special controls require labeling about the known duration of effect. “Permanent” and “for good” need evidence.
Diagnosis first. The injectable label tells clinicians to evaluate for secondary causes such as hyperthyroidism before treating the sweating itself.
FTC rules apply. Sweat-reduction rates, “no side effects” and comparisons are health claims that need competent and reliable scientific evidence, and so do reviews that make them.

What FDA cleared for sweat-reduction devices

FDA product code OUB is named “Instrument For Treatment Of Hyperhidrosis” (openFDA, device data last updated October 19, 2026). It is a Class II code listed under 21 CFR 878.4400, the regulation for electrosurgical cutting and coagulation devices. openFDA returned three 510(k) decisions under it, all substantially equivalent: K103014 (January 28, 2011), K131162 (October 25, 2013) and K150419 (June 19, 2015).

K103014 (January 28, 2011). The indication is the treatment of primary axillary hyperhidrosis, followed by a note: the system “is not indicated for treating hyperhidrosis related to other body areas or generalized hyperhidrosis.” The summary describes a randomized, blinded study of 120 subjects, 81 treated and 39 given a sham treatment, that met its primary endpoint on sweat reduction.
K131162 (October 25, 2013). Same indication and the same note on other body areas.
K150419 (June 19, 2015). The indication adds underarm hair removal and permanent reduction of underarm hair for Fitzpatrick skin types I to IV, with “permanent hair reduction” defined as long-term, stable reduction in regrowing hairs measured at 6, 9 and 12 months. It is marked for prescription use. That definition is for hair, not sweat; it is not a basis for “permanent sweat reduction.”

A second route opened in 2023. FDA granted De Novo request DEN210055 on April 7, 2023, creating product code QVX and a new regulation, 21 CFR 878.4425, for a “skin patch for treatment of hyperhidrosis”: a prescription topical patch that uses a chemical reaction to generate heat in the skin. The decision summary gives the indication as primary axillary hyperhidrosis in adults, and its limitations are specific. Safety and effectiveness have not been demonstrated in patients on therapies that alter perspiration, in people with “excessive sweating” who have not been clinically diagnosed with primary axillary hyperhidrosis, in diffuse or secondary hyperhidrosis, or after earlier underarm procedures. They have not been assessed on other body sites or with repeated use.

The same summary shows why results claims need care. In the pivotal study, 64% of patients in the active group and 44% in the sham group reached a Hyperhidrosis Disease Severity Scale score of 1 or 2 at four weeks, a difference that was statistically significant only in the per-protocol population, not the full analysis set. FDA estimated the burn rate at 8%. Under the special controls in 21 CFR 878.4425, patient and physician labeling must include a summary of the clinical testing, known and potential risks, and information about the known duration of effect.

If you do not know which clearance or grant covers the device in your office, ask the manufacturer for the K or DEN number and read its indications in FDA’s databases before you write anything about it.

What the drug labels say

Searching openFDA drug labels (data last updated October 30, 2026) for primary axillary hyperhidrosis returns three prescription products with that indication by name: one botulinum toxin injection and two topical anticholinergics.

The injectable. Its prescribing information (label effective February 2, 2026) covers severe primary axillary hyperhidrosis that is inadequately managed with topical agents. The label’s limitations of use say that safety and effectiveness for hyperhidrosis in other body areas have not been established, that weakness of hand muscles and drooping eyelids may occur in patients treated for palm and facial sweating, respectively, and that safety and effectiveness for axillary hyperhidrosis have not been established in patients under 18. It tells clinicians to evaluate patients for causes of secondary hyperhidrosis, such as hyperthyroidism, before treating the symptom. In the first placebo-controlled study, the median duration of response after the first treatment was 201 days. The label carries a boxed warning on distant spread of toxin effect and says its units are not interchangeable with other botulinum toxin products.

The topical drugs. Two topical anticholinergics are labeled for primary axillary hyperhidrosis in adults and children 9 years and older (labels effective May 21, 2026 and September 22, 2025). Both labels warn about urinary retention, heat illness in hot environments when sweating stops, and blurred vision that can affect driving, and both list contraindications such as glaucoma.

Two points follow for marketing. First, palms, feet, face and scalp are not within the indication on any of these three labels. Second, FDA’s page on unapproved uses says a provider may generally prescribe an approved drug for an unapproved use when they judge it medically appropriate, but prescribing is not advertising. FDA’s prescription drug ad rule bars a manufacturer’s ad from suggesting uses outside the approved labeling (21 CFR 202.1(e)(4)(i)(a)), a duty written for the manufacturer, packer or distributor (21 USC 352(n)). We found no FDA rule that applies it to a practice’s own service ads as such, but a practice ad that promises “dry palms” is still a health claim under the FTC Act and needs evidence. Our guides to prescription treatment advertising and neuromodulator and injectable advertising cover the rest of the drug side.

“FDA cleared,” “granted” and “approved”

21 CFR 807.97 says a 510(k) clearance does not in any way denote official approval of a device, and that a representation creating that impression is misleading and misbranding. A device authorized through De Novo has been granted, not approved either. Drugs are approved. For devices, 21 USC 396 lets clinicians use a legally marketed device as they judge best for a patient, but says it “shall not change any existing prohibition on the promotion of unapproved uses.”

Wording that fits the record:

“Our device is FDA cleared for the treatment of primary axillary hyperhidrosis” (for a device cleared under OUB with that indication).
“An FDA-authorized prescription patch for primary axillary hyperhidrosis in adults” (for a device under the De Novo).
“An FDA-approved prescription injection for severe underarm sweating not controlled by topical products, in adults.”

Wording that does not:

“FDA approved” for a cleared or De Novo device.
“FDA cleared (or approved) for hands, feet and face,” or any area beyond the underarm.
“FDA approved” next to a treatment area or age group the record does not cover, so the reader assumes FDA reviewed it.

Our guide to medical device marketing claims covers clearance, De Novo and off-label wording across specialties.

What the FTC requires

Section 5 of the FTC Act declares unfair or deceptive acts or practices unlawful (15 USC 45(a)), and section 12 makes it unlawful to disseminate a false advertisement to induce the purchase of drugs, devices or services (15 USC 52). Under 15 USC 55(a)(1), whether an ad is misleading also depends on what it fails to reveal about the consequences of using the product as advertised.

The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence and that the FTC reads an ad for its net impression. Common hyperhidrosis claims that need that support:

Permanence. “Permanent,” “for good” and “never sweat again.” The injectable label reports a median response measured in months, the patch’s safety and effectiveness with repeated use were not assessed, and the one “permanent” definition in the device record is about underarm hair.
Rates. “82% less sweat” or “works for 9 out of 10 patients” needs evidence for your device or drug, your protocol and the measure you name. The patch study shows how much depends on the analysis and the comparison group.
Areas. “Dry hands and feet” or “face and scalp sweating” is a claim beyond every label and clearance we read.
Safety and comfort. “No side effects,” “no downtime” and “safe for everyone” conflict with the burn estimate in the De Novo summary, the boxed warning on the injectable and the anticholinergic warnings.
Comparisons. “Better than injections” or “lasts longer than prescription wipes” is a comparative claim. None of the records we read compares one treatment type with another.

Leaving facts out can mislead too. If results fade and treatment is repeated, if the device needs more than one session, or if a prescription product carries warnings that matter for the patient, say so near the price and the booking button (15 USC 55(a)(1)).

Reviews, testimonials and before-and-after images

Under 16 CFR 255.2(a), an advertiser must have substantiation for what a consumer endorsement conveys, as if it made the claim itself. A featured review saying “I haven’t sweated in two years” carries a duration claim the practice would need to support. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as typical unless the ad clearly and conspicuously discloses the generally expected results.

Sweat is hard to photograph, so practices often show starch-iodine test images or sweat-soaked shirts. If you use them, show the time between images, which treatment and how many sessions, and whether the patient also used another product. Do not use a result from one treatment to sell another, and get written patient authorization before using any patient image. See our guide to patient testimonials and before-and-after photos.

Packages, prices and guarantees

Say what the price covers. Number of sessions or units, one or both underarms, whether the consultation, numbing, follow-up and any touch-up are included.
Former prices must be real. A “was $2,400, now $1,500” comparison needs a former price the practice actually offered in good faith for a reasonably substantial period (16 CFR 233.1(a)).
Guarantees need conditions in plain view. “Dry or your money back” is both a results claim and an offer. See money-back guarantees in healthcare ads.
Do not imply insurance coverage unless you have checked it for the patient’s plan.

Our guides to advertising cash prices and advertising patient financing cover the rest.

What you can say

Which treatment types the practice offers, each described with the indication and the right regulatory word (cleared, granted or approved).
That a clinician examines the patient first and checks for other causes of sweating before treatment.
How many sessions your protocol uses and that effects can fade, with the duration information in the product’s labeling if you cite one.
The main risks the labeling lists, in plain words, near the booking button.
That other options exist, such as topical prescriptions, and that the clinician will discuss them.
Price, inclusions, refund terms and any guarantee conditions.

Leave out: “permanent” or “for good,” “FDA approved” for devices, hands, feet, face or scalp results presented as FDA backed, success rates you cannot support for your own treatment, “no side effects,” comparisons without evidence, and reviews that make any of those claims.

An example (made up)

This illustration is invented. A med spa runs this ad: “FDA approved sweat treatment! Stop underarm, hand and foot sweating PERMANENTLY in one session. 95% success. No side effects. Teens welcome. Was $3,000, now $1,200.”

Fixes: “FDA approved” becomes the correct word for the actual device or drug, with its indication. Hands and feet come off. “PERMANENTLY in one session” comes off unless the med spa has evidence for it. “95% success” needs support for this treatment and a defined measure, or it comes off. “No side effects” comes off. “Teens welcome” comes off for any product whose record is limited to adults. The former price stays only if patients actually paid it for a reasonable period. The page should add the exam and screening for other causes, what a session involves, and how long effects are expected to last.

Checklist

Know the K number, DEN number or drug label behind each treatment you advertise, and read its indications.
Cleared, granted and approved used correctly; no “FDA approved” for devices (21 CFR 807.97).
Only the underarm promoted as within the FDA record; no promotion of other areas as FDA backed (21 USC 396; labels).
Age limits in the labeling reflected in who you target.
No permanent, cure or never-sweat-again claims without competent and reliable scientific evidence (15 USC 45, 52; FTC guidance).
Exam and screening for secondary causes described.
Sessions, duration and main risks stated where the service is sold (15 USC 55(a)(1)).
Reviews and images do not say what the practice could not say, and typical results are disclosed (16 CFR 255.2).
Prices, inclusions, former prices and guarantee conditions are real and clear (16 CFR 233.1).
State rules on who may perform each treatment checked with counsel, especially for med spas.

How we help

We build service pages for dermatology and med spa practices with claims checked against the sources above: website design, healthcare SEO for searches like “excessive sweating treatment near me,” and lead generation campaigns that describe treatments without approval, permanence or body-area overclaims. We do not decide whether a treatment works, we do not give legal opinions, and we are not a law firm. Related guides: laser hair removal clinic marketing, Google Ads for med spas and med spa SEO.

Can we say our sweat-reduction device is FDA approved?

No, if it reached the market through 510(k) clearance or De Novo. 21 CFR 807.97 says a 510(k) clearance does not denote official approval and implying approval is misleading. Use cleared or granted, with the indication.

Can we advertise treatment for sweaty hands or feet?

Not as FDA backed. Every device clearance and De Novo grant we read, and each of the three prescription drugs labeled for hyperhidrosis, is limited to the underarm, and the injectable label says safety and effectiveness in other body areas have not been established. Any results claim for other areas also needs competent and reliable scientific evidence under the FTC Act.

Can we say results are permanent?

Only with evidence for that claim and that treatment. The injectable label reports a median duration of response of 201 days in its first study, the patch was not assessed with repeated use, and the device record’s permanent definition covers underarm hair, not sweat.

Can we advertise to teenagers?

Check the labeling. The injectable label says safety and effectiveness for axillary hyperhidrosis are not established under 18, and the patch indication is for adults. The two topical drugs are labeled for patients 9 and older.

Can we post a review that says the patient never sweats anymore?

Not in your ads unless you could support that claim yourself. Under 16 CFR 255.2, the practice needs substantiation for what a featured endorsement conveys, and central results are likely to be read as typical.

Sources

More in Cash-pay, aesthetic and wellness care

Hyperhidrosis treatment marketing: devices, injections and prescription options